Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

incobotulinumtoxinA

Known as: BoNT-A 
 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

Botulinum Toxin Type ANeuromuscular AgentsNeurotoxins
INJECTION, INCOBOTULINUMTOXIN A, 1 UNIT

Narrower (3)

NT 201Xeominbocouture

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
Objective This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
2017
2017
Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity
Objective: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2016
2016
Randomized, placebo‐controlled trial of incobotulinumtoxina for upper‐limb post‐stroke spasticity
Introduction: Efficacy and safety of incobotulinumtoxinA in post‐stroke upper‐limb spasticity were studied. Methods: Subjects… Expand
2014
2014
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated
Typically, botulinum toxin injections for blepharospasm or cervical dystonia (CD) are administered at approximately 3-month… Expand
  • table 1
  • figure 1
  • table 2
2013
2013
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm
IncobotulinumtoxinA (Xeomin®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous… Expand
  • table 2
  • table 1
  • figure 1
  • figure 2
  • table 3
2013
2013
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia
IncobotulinumtoxinA (Xeomin®, NT 201), a preparation without accessory (complexing) proteins, has shown comparable efficacy and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
2011
Highly Cited
2011
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia
OBJECTIVE IncobotulinumtoxinA differs from available formulations in that it does not have accessory proteins… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2011
Highly Cited
2011
Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay
The biological potency of botulinum toxin (BT) drugs is determined by a standardised LD50 assay. However, the potency labelling… Expand
  • table 1
  • table 2
2011
2011
A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.
  • M. Imhof, U. Kühne
  • The Journal of clinical and aesthetic dermatology
  • 2011
    • Corpus ID: 43319090
OBJECTIVE To investigate the efficacy and safety of incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free… Expand
Highly Cited
2010
Highly Cited
2010
Noninferiority of IncobotulinumtoxinA, Free from Complexing Proteins, Compared with Another Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
BACKGROUND Use of botulinum toxin for esthetic purposes has rapidly expanded over the last 20 years. IncobotulinumtoxinA, also… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE